Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
IMRX
$5.27
$
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Next Earnings
2026-02-25
Beta
0.459
Average Volume
Market Cap
Last Dividend
CIK
0001790340
ISIN
US45254E1073
CUSIP
45254E107
CEO
Benjamin J. Zeskind
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
54
IPO Date
2021-07-30
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company's pipeline, platform, and business strategy. | GlobeNewsWire | 2026-02-18 16:05:00 |
| Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey | Immuneering (NASDAQ: IMRX - Get Free Report) and GRI Bio (NASDAQ: GRI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Immuneering and GRI Bio's | Defense World | 2026-02-01 01:10:49 |
| Insider Buying: Immuneering (NASDAQ:IMRX) Insider Buys $10,501.86 in Stock | Immuneering Corporation (NASDAQ: IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the firm's stock in a transaction on Thursday, January 15th. The shares were acquired at an average price of $4.57 per share, with a total value of $10,501.86. Following the completion of the transaction, the insider directly owned 376,496 shares | Defense World | 2026-01-19 04:44:45 |
| Immuneering Corporation (NASDAQ:IMRX) Short Interest Update | Immuneering Corporation (NASDAQ: IMRX - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Based on an average trading volume of 1,780,211 shares, the | Defense World | 2026-01-19 02:42:47 |
| Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data | Immuneering Corporation remains a Strong Buy after 12-month OS data for atebimetinib + mGnP in 1st-line pancreatic cancer showed a robust 64% rate. IMRX's combination nearly doubles standard-of-care 12-month OS (64% vs. 35%), with a favorable safety profile and regulatory alignment for phase 3 initiation mid-2026. Market overreacted to the OS decline from 9 to 12 months; cross-trial comparisons are misleading and do not reflect the differentiated mechanism of IMRX's MEK inhibitor. | Seeking Alpha | 2026-01-08 17:45:37 |
| Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower | Immuneering Corporation (NASDAQ: IMRX) stock is trading lower on Thursday after the company shared updated data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) with a modified chemotherapy combination (gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer. | Benzinga | 2026-01-08 09:28:42 |
| Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript | Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript | Seeking Alpha | 2026-01-07 18:47:59 |
| Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced positive updated overall survival (OS) and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with over 13 months median follow up time. | GlobeNewsWire | 2026-01-07 16:00:00 |
| Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts | Immuneering Corporation (NASDAQ: IMRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. | Defense World | 2026-01-07 01:30:46 |
| All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy | Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2025-12-29 13:01:00 |
| Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 | Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu | GlobeNewsWire | 2025-12-23 08:00:00 |
| Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is on track to dose the first patient in its planned global Phase 3 registrational trial in first line pancreatic cancer patients in mid-2026, evaluating atebimetinib (320 mg QD) in combination with modified gemcitabine and nab-paclitaxel (mGnP), compared with gemcitabine and nab-paclitaxel (GnP) alone. Notably, the company completed its End-of-Phase 2 (EOP2) interactions with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA). | GlobeNewsWire | 2025-12-17 16:05:00 |
| Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering's addition will become effective prior to market open on Monday, December 22, 2025. | GlobeNewsWire | 2025-12-16 08:00:00 |
| Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts | Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to | Defense World | 2025-12-13 01:16:53 |
| Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? | Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2025-11-26 13:01:16 |
| Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? | The mean of analysts' price targets for Immuneering (IMRX) points to a 126.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | Zacks Investment Research | 2025-11-26 10:56:28 |
| Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference | NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D. | GlobeNewsWire | 2025-11-25 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G/A | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| SC 13G/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-10-21 | 2025-10-21 | View Filing |
| SC 13G | 2025-10-07 | 2025-10-07 | View Filing |
| 4 | 2025-10-07 | 2025-10-07 | View Filing |
| SC 13G | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-09-30 | 2025-09-30 | View Filing |
| 424B5 | 2025-09-25 | 2025-09-25 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| FWP | 2025-09-25 | 2025-09-25 | View Filing |
| FWP | 2025-09-24 | 2025-09-24 | View Filing |
| 424B5 | 2025-09-24 | 2025-09-24 | View Filing |
| 8-K | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| D | 2025-09-09 | 2025-09-09 | View Filing |
| EFFECT | 2025-09-09 | 2025-09-09 | View Filing |
| 424B3 | 2025-09-08 | 2025-09-08 | View Filing |
| S-3 | 2025-09-03 | 2025-09-02 | View Filing |
| 8-K | 2025-08-25 | 2025-08-22 | View Filing |
| EFFECT | 2025-08-21 | 2025-08-21 | View Filing |
| S-3 | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 424B5 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-18 | 2025-06-18 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-16 | 2025-06-16 | View Filing |
| 10-Q | 2025-05-05 | 2025-05-05 | View Filing |
| 8-K | 2025-05-05 | 2025-05-05 | View Filing |
| S-8 | 2025-05-05 | 2025-05-05 | View Filing |
| DEFA14A | 2025-04-21 | 2025-04-21 | View Filing |
| DEF 14A | 2025-04-21 | 2025-04-21 | View Filing |
| 4 | 2025-03-24 | 2025-03-24 | View Filing |
| 3 | 2025-03-24 | 2025-03-24 | View Filing |
| 424B5 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| SC 13G/A | 2025-01-17 | 2025-01-17 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K/A | 2024-10-02 | 2024-10-02 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| 8-K | 2024-09-12 | 2024-09-12 | View Filing |
| 10-Q | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 61.83% | 1.33 | 5 | 0.75 | 1.2 | 83.36 |
| Pivot Points Strategy | 45.27% | 1.2 | 17 | 0.75 | 1.29 | 66.81 |
| Bull Bias | 38.27% | 0.97 | 39 | 0.91 | 1.38 | 59.81 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |